Cryptosporidium hominis gene catalog: A resource for the selection of novel Cryptosporidium vaccine candidates

Database

Volumn 2016, Issue , 2016, Pages

  Ifeonu, Olukemi O ^a,b   Simon, Raphael ^a   Tennant, Sharon M ^a   Sheoran, Abhineet S ^c   Daly, Maria C ^a   Felix, Victor ^a   Kissinger, Jessica C ^d   Widmer, Giovanni ^c   Levine, Myron M ^a   Tzipori, Saul ^c   Silva, Joana C ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b GEORGE MASON UNIVERSITY   (United States)

^c TUFTS UNIVERSITY   (United States)

^d University of Georgia ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARASITE ANTIGEN; PROTOZOAL VACCINE;

ANIMAL; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM; GENETIC DATABASE; GENETICS; GENOME; HUMAN;

ANIMALS; ANTIGENS, PROTOZOAN; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM; DATABASES, GENETIC; GENOME, PROTOZOAN; HUMANS; PROTOZOAN VACCINES;

EID: 85016047914     PISSN: 17580463     EISSN: None     Source Type: Journal    
DOI: 10.1093/database/baw137     Document Type: Article

References (91)

1. Liu, L., Oza, S., Hogan, D. et al. (2015) Global, regional, and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet, 385, 430-440.
2. Kotloff, K.L., Nataro, J.P., Blackwelder, W.C. et al. (2013) Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet, 382, 209-222.
3. Xiao, L., Bern, C., Limor, J. et al. (2001) Identification of 5 types of Cryptosporidium parasites in children in Lima, Peru. J. Infect. Dis., 183, 492-497.
4. Sulaiman, I.M., Hira, P.R., Zhou, L. et al. (2005) Unique endemicity of cryptosporidiosis in children in Kuwait. J. Clin. Microbiol., 43, 2805-2809.
5. Cama, V.A., Bern, C., Sulaiman, I.M. et al. (2003) Cryptosporidium species and genotypes in HIV-positive patients in Lima, Peru. J. Eukaryot. Microbiol., 50 Suppl, 531-533.
6. Tumwine, J.K., Kekitiinwa, A., Bakeera-Kitaka, S. et al. (2005) Cryptosporidiosis and microsporidiosis in Ugandan children with persistent diarrhea with and without concurrent infection with the human immunodeficiency virus. Am. J. Trop. Med. Hyg., 73, 921-925.
7. Arrowood, M.J. (2002) In vitro cultivation of Cryptosporidium species. Clin. Microbiol. Rev., 15, 390-400.
8. Morada, M., Lee, S., Gunther-Cummins, L. et al. (2016) Continuous culture of Cryptosporidium parvum using hollow fiber technology. Int. J. Parasitol., 46, 21-29.
9. Sette, A. and Rappuoli, R. (2010) Reverse vaccinology: developing vaccines in the era of genomics. Immunity, 33, 530-541.
10. Donati, C. and Rappuoli, R. (2013) Reverse vaccinology in the 21st century: improvements over the original design. Ann. N. Y. Acad. Sci., 1285, 115-132.
11. Rappuoli, R. and Covacci, A. (2003) Reverse vaccinology and genomics. Science, 302, 602.
12. Vernikos, G. and Medini, D. (2014) Bexsero(R) chronicle. Pathog. Glob. Health, 108, 305-316.
13. Pizza, M., Scarlato, V., Masignani, V. et al. (2000) Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science, 287, 1816-1820.
14. Heinson, A.I., Woelk, C.H. and Newell, M.L. (2015) The promise of reverse vaccinology. Int. Health, 7, 85-89.
15. Maione, D., Margarit, I., Rinaudo, C.D. et al. (2005) Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science, 309, 148-150.
16. Serruto, D. and Rappuoli, R. (2006) Post-genomic vaccine development. FEBS Lett., 580, 2985-2992.
17. Pulendran, B. (2009) Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat. Rev. Immunol., 9, 741-747.
18. Kelly, D.F. and Rappuoli, R. (2005) Reverse vaccinology and vaccines for serogroup B Neisseria meningitidis. Adv. Exp. Med. Biol., 568, 217-223.
19. Heiges, M., Wang, H., Robinson, E. et al. (2006) CryptoDB: a Cryptosporidium bioinformatics resource update. Nucleic Acids Res., 34, D419-D422.
20. Abrahamsen, M.S., Templeton, T.J., Enomoto, S. et al. (2004) Complete genome sequence of the apicomplexan, Cryptosporidium parvum. Science, 304, 441-445.
21. Xu, P., Widmer, G., Wang, Y. et al. (2004) The genome of Cryptosporidium hominis. Nature, 431, 1107-1112.
22. Ifeonu, O.O., Chibucos, M., Orvis, J. et al. (2016) Annotated draft genome sequences of three species of Cryptosporidium: C. meleagridis isolate UKMEL1, C. baileyi isolate TAMU-09Q1, and C. hominis isolates TU502-2012 and UKH1. Pathog. Dis. Oct; 74(7). pii: ftw080. Epub 2016 Aug 12.
23. Isaza, J.P., Galvan, A.L., Polanco, V. et al. (2015) Revisiting the reference genomes of human pathogenic Cryptosporidium species: reannotation of C. parvum Iowa and a new C. hominis reference. Sci. Rep., 5, 16324.
24. International Human Genome Sequencing, C. (2004) Finishing the euchromatic sequence of the human genome. Nature, 431, 931-945.
25. Altschul, S.F., Madden, T.L., Schaffer, A.A. et al. (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res., 25, 3389-3402.
26. Mistry, J., Finn, R.D., Eddy, S.R. et al. (2013) Challenges in homology search: HMMER3 and convergent evolution of coiled-coil regions. Nucleic Acids Res., 41, e121.
27. Bateman, A., Birney, E., Durbin, R. et al. (2000) The Pfam protein families database. Nucleic Acids Res., 28, 263-266.
28. Apweiler, R., Attwood, T.K., Bairoch, A. et al. (2000) InterPro-an integrated documentation resource for protein families, domains and functional sites. Bioinformatics, 16, 1145-1150.
29. Marchler-Bauer, A., Anderson, J.B., Cherukuri, P.F. et al. (2005) CDD: a conserved domain database for protein classification. Nucleic Acids Res., 33, D192-D196.
30. Emanuelsson, O., Nielsen, H., Brunak, S. et al. (2000) Predicting subcellular localization of proteins based on their N-terminal amino acid sequence. J. Mol. Biol., 300, 1005-1016.
31. Nielsen, H., Engelbrecht, J., Brunak, S. et al. (1997) Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites. Protein Eng., 10, 1-6.
32. Fankhauser, N. and Maser, P. (2005) Identification of GPI anchor attachment signals by a Kohonen self-organizing map. Bioinformatics, 21, 1846-1852.
33. Pierleoni, A., Martelli, P.L. and Casadio, R. (2008) PredGPI: a GPI-anchor predictor. BMC Bioinformatics, 9, 392.
34. Poisson, G., Chauve, C., Chen, X. et al. (2007) FragAnchor: a large-scale predictor of glycosylphosphatidylinositol anchors in eukaryote protein sequences by qualitative scoring. Genomics Proteomics Bioinformatics, 5, 121-130.
35. Krogh, A., Larsson, B., von Heijne, G. et al. (2001) Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. J. Mol. Biol., 305, 567-580.
36. Sonnhammer, E.L., von Heijne, G. and Krogh, A. (1998) A hidden Markov model for predicting transmembrane helices in protein sequences. Proc. Int. Conf. Intell. Syst. Mol. Biol., 6, 175-182.
37. Hoof, I., Peters, B., Sidney, J. et al. (2009) NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics, 61, 1-13.
38. Nielsen, M., Lundegaard, C., Blicher, T. et al. (2007) NetMHCpan, a method for quantitative predictions of peptide binding to any HLAA and -B locus protein of known sequence. PLoSOne, 2, e796.
39. Karosiene, E., Rasmussen, M., Blicher, T. et al. (2013) NetMHCIIpan-3.0, a common pan-specificMHCclass II prediction method including all three human MHC class II isotypes, HLA-DR, HLA-DP andHLA-DQ. Immunogenetics, 65, 711-724.
40. Trapnell, C., Pachter, L. and Salzberg, S.L. (2009) TopHat: discovering splice junctions with RNA-Seq. Bioinformatics, 25, 1105-1111.
41. Wu, T.D. and Watanabe, C.K. (2005) GMAP: a genomic mapping and alignment program for mRNA and EST sequences. Bioinformatics, 21, 1859-1875.
42. Parra, G., Bradnam, K. and Korf, I. (2007) CEGMA: a pipeline to accurately annotate core genes in eukaryotic genomes. Bioinformatics, 23, 1061-1067.
43. Lee, E., Helt, G.A., Reese, J.T. et al. (2013) Web Apollo: a webbased genomic annotation editing platform. Genome Biol., 14, R93.
44. Walker, J.M. (2005) The Proteomics Protocols Handbook. Humana Press, Totowa, NJ.
45. Gupta, R. and Brunak, S. (2002) Prediction of glycosylation across the human proteome and the correlation to protein function. Pac Symp Biocomput., 310-22.
46. Steentoft, C., Vakhrushev, S.Y., Joshi, H.J. et al. (2013) Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology. EMBO J., 32, 1478-1488.
47. Chauhan, J.S., Rao, A. and Raghava, G.P. (2013) In silico platform for prediction of N-, O- and C-glycosites in eukaryotic protein sequences. PLoS One, 8, e67008.
48. Lander, E.S., Linton, L.M., Birren, B. et al. (2001) Initial sequencing and analysis of the human genome. Nature, 409, 860-921.
49. Crabtree, J., Angiuoli, S.V., Wortman, J.R. et al. (2007) Sybil: methods and software for multiple genome comparison and visualization. Methods Mol. Biol., 408, 93-108.
50. Li, H. and Durbin, R. (2009) Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics, 25, 1754-1760.
51. Li, H., Handsaker, B., Wysoker, A. et al. (2009) The sequence alignment/map format and SAMtools. Bioinformatics, 25, 2078-2079.
52. McKenna, A., Hanna, M., Banks, E. et al. (2010) The Genome Analysis Toolkit: a MapReduce framework for analyzing nextgeneration DNA sequencing data. Genome Res., 20, 1297-1303.
53. Sanderson, S.J., Xia, D., Prieto, H. et al. (2008) Determining the protein repertoire of Cryptosporidium parvum sporozoites. Proteomics, 8, 1398-1414.
54. Bouzid, M., Hunter, P.R., Chalmers, R.M. et al. (2013) Cryptosporidium pathogenicity and virulence. Clin. Microbiol. Rev., 26, 115-134.
55. O'Hara, S.P., Yu, J.R. and Lin, J.J. (2004) A novel Cryptosporidium parvum antigen, CP2, preferentially associates with membranous structures. Parasitol. Res., 92, 317-327.
56. Petersen, C., Gut, J., Doyle, P.S. et al. (1992) Characterization of a>900, 000-M(r) Cryptosporidium parvum sporozoite glycoprotein recognized by protective hyperimmune bovine colostral immunoglobulin. Infect. Immun., 60, 5132-5138.
57. Forney, J.R., Yang, S., Du, C. et al. (1996) Efficacy of serine protease inhibitors against Cryptosporidium parvum infection in a bovine fallopian tube epithelial cell culture system. J. Parasitol., 82, 638-640.
58. Okhuysen, P.C., Chappell, C.L., Kettner, C. et al. (1996) Cryptosporidium parvum metalloaminopeptidase inhibitors prevent in vitro excystation. Antimicrob. Agents Chemother., 40, 2781-2784.
59. Riggs, M.W., Stone, A.L., Yount, P.A. et al. (1997) Protective monoclonal antibody defines a circumsporozoite-like glycoprotein exoantigen of Cryptosporidium parvum sporozoites and merozoites. J. Immunol., 158, 1787-1795.
60. Strong, W.B., Gut, J. and Nelson, R.G. (2000) Cloning and sequence analysis of a highly polymorphic Cryptosporidium parvum gene encoding a 60-kilodalton glycoprotein and characterization of its 15- and 45-kilodalton zoite surface antigen products. Infect. Immun., 68, 4117-4134.
61. Cevallos, A.M., Bhat, N., Verdon, R. et al. (2000) Mediation of Cryptosporidium parvum infection in vitro by mucin-like glycoproteins defined by a neutralizing monoclonal antibody. Infect. Immun., 68, 5167-5175.
62. Cevallos, A.M., Zhang, X., Waldor, M.K. et al. (2000) Molecular cloning and expression of a gene encoding Cryptosporidium parvum glycoproteins gp40 and gp15. Infect. Immun., 68, 4108-4116.
63. Perkins, M.E., Riojas, Y.A., Wu, T.W. et al. (1999) CpABC, a Cryptosporidium parvum ATP-binding cassette protein at the host-parasite boundary in intracellular stages. Proc. Natl. Acad. Sci. U. S. A., 96, 5734-5739.
64. Khramtsov, N.V., Tilley, M., Blunt, D.S. et al. (1995) Cloning and analysis of a Cryptosporidium parvum gene encoding a protein with homology to cytoplasmic form Hsp70. J. Eukaryot. Microbiol., 42, 416-422.
65. O'Connor, R.M., Burns, P.B., Ha-Ngoc, T. et al. (2009) Polymorphic mucin antigens CpMuc4 and CpMuc5 are integral to Cryptosporidium parvum infection in vitro. Eukaryot. Cell., 8, 461-469.
66. Manque, P.A., Tenjo, F., Woehlbier, U. et al. (2011) Identification and immunological characterization of three potential vaccinogens against Cryptosporidium species. Clin. Vaccine Immunol., 18, 1796-1802.
67. Doro, F., Liberatori, S., Rodriguez-Ortega, M.J. et al. (2009) Surfome analysis as a fast track to vaccine discovery: identification of a novel protective antigen for Group B Streptococcus hypervirulent strain COH1. Mol. Cell. Proteomics, 8, 1728-1737.
68. Holmes, E.C. (2004) Adaptation and immunity. PLoS Biol., 2, E307.
69. Yang, Z. and Bielawski, J.P. (2000) Statistical methods for detecting molecular adaptation. Trends Ecol. Evol., 15, 496-503.
70. Conway, D.J. (2015) Paths to a malaria vaccine illuminated by parasite genomics. Trends Genet., 31, 97-107.
71. Mu, J., Awadalla, P., Duan, J. et al. (2007) Genome-wide variation and identification of vaccine targets in the Plasmodium falciparum genome. Nat. Genet., 39, 126-130.
72. Neafsey, D.E., Juraska, M., Bedford, T. et al. (2015) Genetic diversity and protective efficacy of the RTS, S/AS01 malaria vaccine. N. Engl. J. Med., 373, 2025-2037.
73. Ouattara, A., Takala-Harrison, S., Thera, M.A. et al. (2013) Molecular basis of allele-specific efficacy of a blood-stage malaria vaccine: vaccine development implications. J. Infect. Dis., 207, 511-519.
74. Takala, S.L., Coulibaly, D., Thera, M.A. et al. (2009) Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. Sci. Transl. Med., 1, 2ra5.
75. Schwarz, F. and Aebi, M. (2011) Mechanisms and principles of N-linked protein glycosylation. Curr. Opin. Struct. Biol., 21, 576-582.
76. Van den Steen, P., Rudd, P.M., Dwek, R.A. et al. (1998) Concepts and principles of O-linked glycosylation. Crit. Rev. Biochem. Mol. Biol., 33, 151-208.
77. Odenthal-Schnittler, M., Tomavo, S., Becker, D. et al. (1993) Evidence for N-linked glycosylation in Toxoplasma gondii. Biochem. J., 291 (Pt 3), 713-721.
78. Dieckmann-Schuppert, A., Bause, E. and Schwarz, R.T. (1994) Glycosylation reactions in Plasmodium falciparum, Toxoplasma gondii, and Trypanosoma brucei brucei probed by the use of synthetic peptides. Biochim. Biophys. Acta, 1199, 37-44.
79. Dieckmann-Schuppert, A., Bender, S., Odenthal-Schnittler, M. et al. (1992) Apparent lack of N-glycosylation in the asexual intraerythrocytic stage of Plasmodium falciparum. Eur. J. Biochem., 205, 815-825.
80. Kimura, E.A., Couto, A.S., Peres, V.J. et al. (1996) N-linked glycoproteins are related to schizogony of the intraerythrocytic stage in Plasmodium falciparum. J. Biol. Chem., 271, 14452-14461.
81. Luk, F.C., Johnson, T.M. and Beckers, C.J. (2008) N-linked glycosylation of proteins in the protozoan parasite Toxoplasma gondii. Mol. Biochem. Parasitol., 157, 169-178.
82. Gonzalez, C., Hone, D., Noriega, F.R. et al. (1994) Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans. J. Infect. Dis., 169, 927-931.
83. Gonzalez, C.R., Noriega, F.R., Huerta, S. et al. (1998) Immunogenicity of a Salmonella typhi CVD 908 candidate vaccine strain expressing the major surface protein gp63 of Leishmania mexicana mexicana. Vaccine, 16, 1043-1052.
84. Ruiz-Perez, F., Leon-Kempis, R., Santiago-Machuca, A. et al. (2002) Expression of the Plasmodium falciparum immunodominant epitope (NANP)(4) on the surface of Salmonella enterica using the autotransporter MisL. Infect. Immun., 70, 3611-3620.
85. de Barra, E., Hodgson, S.H., Ewer, K.J. et al. (2014) A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS. PLoS One, 9, e115161.
86. Biswas, S., Choudhary, P., Elias, S.C. et al. (2014) Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure. PLoS One, 9, e107903.
87. Stewart, V.A., McGrath, S.M., Dubois, P.M. et al. (2007) Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS, S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Infect. Immun., 75, 2283-2290.
88. Jones, R.M., Chichester, J.A., Mett, V. et al. (2013) A plantproduced Pfs25 VLP malaria vaccine candidate induces persistent transmission blocking antibodies against Plasmodium falciparum in immunized mice. PLoS One, 8, e79538.
89. Ord, R.L., Caldeira, J.C., Rodriguez, M. et al. (2014) A malaria vaccine candidate based on an epitope of the Plasmodium falciparum RH5 protein. Malar. J., 13, 326.
90. Burkhard, P. and Lanar, D.E. (2015) Malaria vaccine based on self-assembling protein nanoparticles. Expert. Rev. Vaccines, 14, 1525-1527.
91. El-Kamary, S.S., Cohen, M.B., Bourgeois, A.L. et al. (2013) Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli. Clin. Vaccine Immunol., 20, 1764-1770.